DTIL Precision BioSciences, Inc.

NASDAQ
$7.43

Precision BioSciences, Inc. (DTIL) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.97 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.1% since its last earnings release on August 6, 2026.

Precision BioSciences Beat Consensus Estimates
Thursday, August 6, 2026 · 7:01 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.97)
Rev est $10.9M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.44

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.

Sector

Healthcare

Industry

Biotechnology